About the Report
- The bispecific space is continuing to grow with a 56% average annual growth in the initiation of trials between 2010 – 2021 and a 78% average annual growth in drugs entering the clinic between 2001 – 2021.
- A total of four approvals in H1 2022 and with various therapies being in late-stage clinical development close to BLA submission we can expect more approvals in the space.
- With the first immune checkpoint targeting bispecific being approved this year, we are seeing a shift in the space with growing interest in bispecifics being investigated for the treatment of solid tumors.
- Download the Trial Landscape 2022 analysis for a detailed report of current updates.
Find out more
The data from this mid-year landscape review is available on the Beacon Bispecific platform.
Speak with our expert Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your bispecific questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
